How To Use The Inhaler

Use twice a day for the maintenance treatment of COPD

TUDORZA^®PRESSAIR^® (aclidinium bromide inhalation powder) is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy).¹

Patient Feedback in 3 Steps¹:

TUDORZA PRESSAIR Instructions Step 1

1. Ready Before Inhalation

Remove cap and hold upright.
PRESS and RELEASE the green button.
Check the color-controlled window. GREEN means the medicine is READY for inhalation.
Before you put the inhaler in your mouth, breathe out completely. Do not breathe out into the inhaler. Then place your lips tightly around the mouthpiece.

TUDORZA PRESSAIR Instructions Step 2

2. During Inhalation

TAKE A STRONG, DEEP BREATH IN.
A "CLICK" will sound during inhalation when the inhaler is used correctly.
Keep breathing in as long as possible after you hear the "CLICK."*

TUDORZA PRESSAIR Instructions Step 3

3. Confirm after Inhalation

Remove the inhaler from your mouth and hold your breath for as long as possible, and then slowly breathe out, away from the inhaler.
CONFIRM the color-controlled window has turned from green to RED to ensure the full dose has been inhaled correctly.

If you would like to print or keep a copy of the instructions, please select the "download instructions" button below.

DOWNLOAD INSTRUCTIONS

For a complete description of how to use the TUDORZA PRESSAIR inhaler, please see the Instructions for Use in the Full Prescribing Information.

How To Use Video

Watch this video on using TUDORZA to help your patients inhale their dose correctly.

See Full Dosing Information

INDICATIONS AND USAGE

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy)
Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any worsening of glaucoma or worsening of urinary retention develop
The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively. In a long-term cardiovascular safety trial of up to 3 years, the adverse reactions (occurring at a rate of ≥2% and more common than placebo) were nausea, back pain, cough, hypertension, sinusitis, constipation, arthralgia, anemia, muscle spasms, cardiac failure congestive, cellulitis, and gastroesophageal reflux disease

Please also see the Full Prescribing Information, including Patient Information.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 877-411-2510 or at medinfoUS@covispharma.com, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

MORE IMPORTANT SAFETY INFORMATION

Who should not use TUDORZA PRESSAIR?
TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients

INDICATIONS AND USAGE

TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

TUDORZA PRESSAIR is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to aclidinium bromide or any of the excipients
TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (i.e. rescue therapy)
Immediate hypersensitivity reactions, including anaphylaxis, angioedema (swelling of lips, tongue, or throat), urticaria, rash, bronchospasm, or itching have occurred after administration of TUDORZA PRESSAIR. Additionally, inhaled medicines, including TUDORZA PRESSAIR, may cause paradoxical bronchospasm. If any of these occurs, treatment with TUDORZA PRESSAIR should be stopped and other treatments considered
TUDORZA PRESSAIR should be used with caution in patients with narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any worsening of glaucoma or worsening of urinary retention develop
The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA PRESSAIR vs placebo, respectively. In a long-term cardiovascular safety trial of up to 3 years, the adverse reactions (occurring at a rate of ≥2% and more common than placebo) were nausea, back pain, cough, hypertension, sinusitis, constipation, arthralgia, anemia, muscle spasms, cardiac failure congestive, cellulitis, and gastroesophageal reflux disease

Please also see the Full Prescribing Information, including Patient Information.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Covis Pharma at 877-411-2510 or at medinfoUS@covispharma.com, or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

REFERENCES: 1. Tudorza^® Pressair^®(aclidinium bromide inhalation powder) [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; February, 2021.